journal
MENU ▼
Read by QxMD icon Read
search

Inflammatory Bowel Diseases

journal
https://www.readbyqxmd.com/read/28195852/a-real-life-population-pharmacokinetic-study-reveals-factors-associated-with-clearance-and-immunogenicity-of-infliximab-in-inflammatory-bowel-disease
#1
Johannan F Brandse, Diane Mould, Oscar Smeekes, Yaël Ashruf, Sabine Kuin, Anne Strik, Gijs R van den Brink, Geert R DʼHaens
BACKGROUND: Several factors influencing the pharmacokinetics of infliximab (IFX) in inflammatory bowel disease (IBD) have been identified. We studied the impact of patient, disease, and treatment characteristics on clearance and immunogenicity of IFX in a real-world patient-with-IBD cohort. METHODS: Serum concentrations of IFX and antibodies to IFX (ATIs) were measured in patients with IBD at a single center using an enzyme-linked immunosorbent assay and radioimmunoassay...
February 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28195851/maternal-infections-that-would-warrant-antibiotic-use-antepartum-or-peripartum-are-not-a-risk-factor-for-the-development-of-ibd-a-population-based-analysis
#2
Charles N Bernstein, Charles Burchill, Laura E Targownik, Harminder Singh, Jean Eric Ghia, Leslie L Roos
BACKGROUND: We aimed to determine whether maternal antenatal or perinatal infections (and thereby use of antibiotics) increase the risk of developing inflammatory bowel disease (IBD) in their offspring. METHODS: The University of Manitoba IBD Epidemiology Database contains records of all Manitobans diagnosed with IBD from 1984 to 2010. Each individual with IBD is matched to 10 controls. Subjects' medical system contacts are identified using a unique deidentified personal health identification number...
February 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28178003/efficacy-and-safety-of-vedolizumab-for-induction-of-remission-in-inflammatory-bowel-disease-the-israeli-real-world-experience
#3
Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar-Gil Shitrit, Eran Israeli, Doron Schwartz, Eran Zittan, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan
BACKGROUND: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the "real world" efficacy and safety of VDZ in a large national patient cohort. METHODS: Patients with inflammatory bowel disease treated with VDZ were prospectively followed for 14 weeks. Patients who completed the induction protocol (week 0/2/6/14) or discontinued the treatment before week 14 for adverse events (AEs) or primary nonresponse were included...
February 7, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28178002/self-efficacy-and-resilience-are-useful-predictors-of-transition-readiness-scores-in-adolescents-with-inflammatory-bowel-diseases
#4
Katrine Carlsen, Nichola Haddad, Julia Gordon, Becky Lin Phan, Nanci Pittman, Keith Benkov, Marla C Dubinsky, Laurie Keefer
BACKGROUND: Adolescence is a vulnerable period for those afflicted with inflammatory bowel disease (IBD). There is limited knowledge of factors influencing transition readiness in this population. We sought to determine whether self-efficacy and resilience would be informative predictors of transition readiness independent of age. METHODS: Patients with IBD aged 16 to 23 years cared for in a pediatric setting were prospectively enrolled. On entry, patients filled out the Transition Readiness Assessment Questionnaire (TRAQ); IBD Self-Efficacy Scale-Adolescent (IBD-SES-A); and the Connor-Davidson Resilience Scale...
February 7, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28151736/nodular-regenerative-hyperplasia-of-the-liver-in-patients-with-ibd-treated-with-allopurinol-thiopurine-combination-therapy
#5
Margien L Seinen, Dirk P van Asseldonk, Nanne K de Boer, Gerd Bouma, Carin M van Nieuwkerk, Chris J Mulder, Elisabeth Bloemena, Adriaan A van Bodegraven
BACKGROUND: Thiopurine therapy, particularly thioguanine, has been associated with nodular regenerative hyperplasia (NRH) of the liver. Combination therapy of allopurinol and an adapted low-dose thiopurine leads to a pharmacokinetic profile that has similarities to that of thioguanine. Therefore, allopurinol-thiopurine combination therapy may also be associated with NRH of the liver. We assessed the prevalence of NRH in patients with inflammatory bowel disease (IBD) treated with allopurinol-thiopurine combination therapy by liver biopsy specimen examination...
February 1, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28151735/do-thiopurines-reduce-the-risk-of-surgery-in-elderly-onset-inflammatory-bowel-disease-a-20-year-national-population-based-cohort-study
#6
Christopher Alexakis, Sonia Saxena, Vivek Chhaya, Elizabeth Cecil, Vasa Curcin, Richard Pollok
BACKGROUND: Evidence that thiopurines impact on the risk of surgery in elderly onset inflammatory bowel disease (EO-IBD) is lacking. We aimed to compare the rates of surgery in EO-IBD (>60 years at diagnosis) with adult-onset IBD (18-59 yrs), and examine the impact of thiopurines on surgical risk in EO-IBD. METHODS: Using a U.K. database between 1990 and 2010, we compared rates of surgery between adult-onset IBD and EO-IBD using survival analysis. Ulcerative colitis (UC) and Crohn's disease (CD) were analyzed separately...
February 1, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28146006/letters-to-the-editor
#7
Abhik Bhattacharya
No abstract text is available yet for this article.
January 31, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28146005/elevated-c-reactive-protein-in-asymptomatic-crohn-s-disease-patients-listen-to-the-sound-of-silence
#8
Cristiano Pagnini, Maria Benedetta Mariani, Vito Domenico Corleto, Gianfranco Delle Fave
No abstract text is available yet for this article.
January 31, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28146004/epithelial-specific-toll-like-receptor-tlr-5-activation-mediates-barrier-dysfunction-in-experimental-ileitis
#9
Loris R Lopetuso, Ruo Jia, Xiao-Ming Wang, Li-Guo Jia, Valentina Petito, Wendy A Goodman, Jon B Meddings, Fabio Cominelli, Brian K Reuter, Theresa T Pizarro
BACKGROUND: A large body of evidence supports a central role of TLR5 and its natural ligand, flagellin, in Crohn's disease (CD), with the precise mechanism(s) still unresolved. METHODS: We investigated the role of flagellin/TLR5 in SAMP1/YitFc (SAMP) mice, a spontaneous model of Crohn's disease-like ileitis. RESULTS: Ileal Tlr5 and serum antiflagellin IgG antibodies were increased in SAMP before the onset of inflammation and during established disease; these trends were abrogated in the absence of colonizing commensal bacteria...
January 31, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28146003/comparative-effectiveness-of-mesalamine-sulfasalazine-corticosteroids-and-budesonide-for-the-induction-of-remission-in-crohn-s-disease-a-bayesian-network-meta-analysis
#10
Stephanie Coward, M Ellen Kuenzig, Glen Hazlewood, Fiona Clement, Kerry McBrien, Rebecca Holmes, Remo Panaccione, Subrata Ghosh, Cynthia H Seow, Ali Rezaie, Gilaad G Kaplan
BACKGROUND: Induction treatment of mild-to-moderate Crohn's disease is controversial. PURPOSE: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn's disease. DATA SOURCES: We identified randomized controlled trials from existing Cochrane reviews and an updated literature search in Medline, EMBASE, and CENTRAL to November 2015. STUDY SELECTION: We included randomized controlled trials (n = 22) in adult patients with Crohn's disease that compared budesonide, sulfasalazine, mesalamine, or corticosteroids with placebo or each other, for the induction of remission (8-17 wks)...
January 31, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28146002/development-of-the-ibd-disk-a-visual-self-administered-tool-for-assessing-disability-in-inflammatory-bowel-diseases
#11
Subrata Ghosh, Edouard Louis, Laurent Beaugerie, Peter Bossuyt, Guillaume Bouguen, Arnaud Bourreille, Marc Ferrante, Denis Franchimont, Karen Frost, Xavier Hebuterne, John K Marshall, Ciara OʼShea, Greg Rosenfeld, Chadwick Williams, Laurent Peyrin-Biroulet
BACKGROUND: The Inflammatory bowel disease (IBD) Disability Index is a validated tool that evaluates functional status; however, it is used mainly in the clinical trial setting. We describe the use of an iterative Delphi consensus process to develop the IBD Disk-a shortened, self-administered adaption of the validated IBD Disability Index-to give immediate visual representation of patient-reported IBD-related disability. METHODS: In the preparatory phase, the IBD CONNECT group (30 health care professionals) ranked IBD Disability Index items in the perceived order of importance...
January 31, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28129289/ultrasound-shear-wave-elastography-and-contrast-enhancement-effective-biomarkers-in-crohn-s-disease-strictures
#12
Cathy Lu, Xianyong Gui, Wenqian Chen, Tak Fung, Kerri Novak, Stephanie R Wilson
BACKGROUND: Inflammation, fibrosis, and muscular hypertrophy lead to thickened bowel in Crohn's disease forming strictures. Ultrasound shear wave elastography (SWE) measures bowel wall stiffness. Contrast-enhanced ultrasound (CEUS) uniquely detects bowel wall inflammation. We aim to correlate SWE of ileal Crohn's disease in vivo to CEUS peak enhancement and pathology grades of inflammation, fibrosis, and muscular hypertrophy. METHODS: In a prospective institutional review board-approved study, 105 consecutive ileal patients with Crohn's disease received ultrasound...
January 26, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28129288/long-term-efficacy-and-safety-of-adalimumab-in-pediatric-patients-with-crohn-s-disease
#13
William A Faubion, Marla Dubinsky, Frank M Ruemmele, Johanna Escher, Joel Rosh, Jeffrey S Hyams, Samantha Eichner, Yao Li, Nattanan Reilly, Roopal B Thakkar, Anne M Robinson, Andreas Lazar
BACKGROUND: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn's disease. Long-term efficacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported. METHODS: Patients who completed IMAgINE 1 could enroll in IMAgINE 2. Endpoints assessed from weeks 0 to 240 of IMAgINE 2 were Pediatric Crohn's Disease Activity Index remission (Pediatric Crohn's Disease Activity Index ≤ 10) and response (Pediatric Crohn's Disease Activity Index decrease ≥15 from IMAgINE 1 baseline) using observed analysis and hybrid nonresponder imputation (hNRI)...
January 26, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28129287/development-and-validation-of-a-questionnaire-to-assess-the-quality-of-life-in-patients-with-inflammatory-bowel-disease-in-mainland-china
#14
Jiayin Ruan, Yan Chen, Yunxian Zhou
BACKGROUND: Inflammatory bowel disease (IBD) affects the quality of patients' life in many ways. The aim of this study was to develop and validate a mainland Chinese version of IBD quality-of-life questionnaire for ulcerative colitis (UC) and Crohn's disease (CD). METHODS: A draft questionnaire containing 30 items was generated from a descriptive qualitative study, literature review and consulting with IBD patients and experts. The validity, discriminant ability, reliability, and sensitivity to change were validated in 336 patients with IBD...
January 26, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28129286/methotrexate-for-refractory-crohn-s-disease-compared-with-thiopurines-a-retrospective-non-head-to-head-controlled-study
#15
Zicheng Huang, Kang Chao, Miao Li, Min Zhi, Jian Tang, Pinjin Hu, Xiang Gao
BACKGROUND: This study assessed the efficacy and safety of methotrexate (MTX) compared with thiopurines (TPs) for refractory Crohn's disease. METHODS: Fifty-one consecutive patients who were refractory or intolerant to TPs and steroid-dependent were retrospectively analyzed. MTX (20 mg/wk, subcutaneous) was adopted for inducing and maintaining clinical remission (CR). Fifty-seven patients who were naive to immunosuppressant and prescribed azathioprine (2 mg·kg·d) or mercaptopurine (1 mg·kg·d) were simultaneously recruited...
January 26, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28125563/author-index
#16
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28125562/o-014-bacterial-sensor-nod2-deletion-causes-th2-inflammatory-bowel-disease-improvement-without-inducing-acute-metatranscriptomic-dysbiosis-in-mice
#17
Alexander Rodriguez-Palacios, Daniele Corridoni, Gabriella Di Stefano, Luca Di Martino, D A Antonopoulos, Eugene Chang, T T Pizarro, Fabio Cominelli
BACKGROUND: Although single nucleotide polymorphisms in the NOD2 (nucleotide-binding oligomerization domain-containing 2) gene have been associated with the pathogenesis of Crohn's disease (CD), little is known about the role of nonpolymorphic wild-type (WT) NOD2 genes in the gut. To date, most animal studies addressing the role of WT NOD2 have been conducted using healthy (ileitis/colitis-free) mouse strains, and have attributed a modulating effect to the gut microbiome, partly based on 16S rRNA sequencing...
February 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28125561/o-013-dietary-emulsifiers-directly-impact-the-human-gut-microbiota-increasing-its-pro-inflammatory-potential-and-ability-to-induce-intestinal-inflammation
#18
Benoit Chassaing, Tom Van de Wiele, Andrew Gewirtz
BACKGROUND: The intestinal microbiota plays a central role in the development of many chronic inflammatory diseases including inflammatory bowel disease. Accordingly, we recently demonstrated that administration of substances that alter microbiota composition, including the dietary emulsifiers polysorbate 80 (P80) and carboxymethylcellulose (CMC), promotes such inflammatory disorders. However, because inflammation itself impacts microbiota composition, it is very difficult to discern the extent to which these compounds or other substances act directly upon the microbiota versus acting on host parameters that promote inflammation, which subsequently reshapes impacts the microbiota...
February 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28125560/o-012-il-36-signaling-controls-the-induced-regulatory-t-cell-th9-cell-balance-and-gut-inflammation
#19
Akihito Harusato, Hirohito Abo, Vu Ngo, Samuel Yi, Satoru Osuka, Jakob Kohlmeier, Jian-Dong Li, Andrew Gewirtz, Asma Nusrat, Timothy Denning
BACKGROUND: In the United States over 1.4 million people suffer from inflammatory bowel disease (IBD). Therefore, there is a pressing need for the development of novel molecular therapeutics targeting pro-inflammatory mediators. Recently a novel interleukin-1 family member, IL-36γ was shown to be up-regulated in patients with inflammatory bowel disease (IBD) and to play an important role in healing of acute intestinal damage in mice, however, the function of IL-36γ with regards to T helper (TH) cell differentiation during gut inflammation remains undefined...
February 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28125559/o-011-low-dose-il-2-administration-expands-human-regulatory-t-cells-in-patients-with-uc-and-humanized-mice-and-protects-against-experimental-colitis
#20
Jeremy Goettel, Daniel Kotlarz, David Illig, James Canavan, Jessica Allegretti, Matthew Hamilton, Ryan Kelly, Alexandra Griffith, Madeline Carellas, Anastasia Nelina, Athos Bousvaros, Joshua Korzenik, Scott Snapper
BACKGROUND: Treg dysfunction or deficiency results in unopposed immune activation and autoimmunity. Interleukin-2 (IL-2) is critical for the expansion, suppressive function, and maintenance of Tregs. Although conventional T cells and NK cells respond to IL-2, Tregs are more sensitive to lower concentrations of IL-2 due to constitutive expression of CD25, the high affinity IL-2 receptor. Low-dose IL-2 therapies have shown to preferentially expand Tregs and ameliorate manifestations of graft versus host disease (Koreth et al...
February 2017: Inflammatory Bowel Diseases
journal
journal
32277
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"